The case for a value-based formulary: Striving for total lowest net cost

Managed Care Interface

Volumn 20, Issue 4, 2007, Pages 42-47

  Weart, Wayne ^a,c,d,e   Bauman, Gary R ^b  

^a Pharmacy and Therapeutics Committee   (United States)

^b Health Trans LLC   (United States)

^c Department of Pharmacy and Clinical Sciences ^*  (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CLARITHROMYCIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; ERYTHROMYCIN; EZETIMIBE; FLUINDOSTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PRAVASTATIN; PROTEINASE INHIBITOR; ROFECOXIB; SIMVASTATIN; VALDECOXIB; VERAPAMIL;

ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG MARKETING; DRUG SAFETY; EVIDENCE BASED MEDICINE; FINANCIAL INFORMATION SYSTEM; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH PLAN EMPLOYER DATA AND INFORMATION SET; HUMAN; ORGANIZATION; PATIENT COMPLIANCE; PHARMACY; RESPONSIBILITY; SIDE EFFECT; SKIN MANIFESTATION;

COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DISEASE MANAGEMENT; DRUG COSTS; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FORMULARIES; HUMANS; MANAGED CARE PROGRAMS; PHARMACEUTICAL SERVICES; PHARMACY AND THERAPEUTICS COMMITTEE; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES;

EID: 34247360053     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. American College of Cardiology (www.acc.org/ qualityandscience/clinical/guidelines/failure/update/index.pdf), 2005.
2. Heart Failure Society of America: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006;12:e1-e119.
3. Gemmell I, Heller RF, McElduff P, et al: Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. J Epidemiol Community Health 2005;59:1041-1046.
4. Packer M, Poole-Wilson PA, Armstrong PW, et al: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-2318.
5. Starke PR, Weaver J, Chowdhury BA: Boxed warning added to promethazine labeling for pediatric use. NEJM 2005;352:2653.
6. Promethazine HCl (marketed as Phenergan) information. U.S. Food and Drug Administration (www.fda.gov/cder/drug/infopage/promethazine/default.htm), April 25, 2006.
7. Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
8. Dagenais GR, Yusuf S, Bourassa MG, et al: Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. Circulation 2001;104:522-526.
9. Pilote L, Abrahamowicz M, Rodrigues E, et al: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: A class effect? Ann Intern Med 2004;141:102-112.
10. Liljas B, Stadhl E, Pauwels RA: Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurised metered dose inhaler in patients with asthma. Pharmacoeconomics 1997;12(2 Pt 2):267-277.
11. Howarth J, Ledger G, O'Reilly JF: Comparison of benefits and costs of dry powder (DPI) and metered dose (MDI) inhaler treatment of asthma. Eur Respir J 1997;10(suppl 25):127s.
12. Smith I, Parry-Billings M: The inhalers of the future? A review of dry-powder devices on the market today. Pulmon Pharmacol Ther 2003;16:79-95.
13. Taylor A, Ziesche S, Yancy C, et al: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057
14. Bloche MG: Race-based therapeutics (commentary). N Engl J Med 2004;351:2035-2037.
15. FDA public health advisory - FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). The U.S. Food and Drug Administration (www.fda.gov/cder/drug/advisory/COX2.htm), April 7, 2005.
16. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). The U.S. Food and Drug Administration (www.fda.gov/cder/drug/infopage/COX2/default.htm), July 18, 2005.
17. Questions and answers on proposed rule for labeling changes to over-the-counter pain relievers. Food and Drug Administration (www.fda.gov/cder/offices/otc/labeling_changeqa.htm), December 19, 2006.
18. Bottorff MB: Statin safety and drug interactions: Clinical implications. Am J Cardiol 2006;97(suppl):27C-31C.
19. Drugs for lipids - treatment guidelines. The Medical Letter 2005;3(31):15-22.
20. Expert panel report: Guidelines for the diagnosis and management of asthma - update on selected topics 2002. National Heart, Lung, and Blood Institute (www.nhlbi.nih.gov/guidelines/asthma/asthmafullrpt.pdf), June 2003.
21. HR Policy Association certifies ten pharmacy benefit managers willing to provide full transparency in drug contracting. HR Policy Association (www.hrpolicy.org/initiatives/06-912%2010%20certified%20pbms%20pr.pdf), July 24, 2006.